UNDERWRITING AGREEMENTUnderwriting Agreement • September 11th, 2022
Contract Type FiledSeptember 11th, 2022Desjardins Securities Inc. (the “Lead Underwriter”), as lead underwriter, and iA Private Wealth Inc., Leede Jones Gable Inc., Paradigm Capital Inc. and Research Capital Corporation (collectively with the Lead Underwriter, the “Underwriters” and each individually, an “Underwriter”) hereby offers and agrees to purchase on a private placement, “bought deal” basis, or alternatively to arrange for substituted purchasers (the “Substituted Purchasers”) in the Qualifying Jurisdictions (as defined below) to purchase, from Valeo Pharma Inc. (the “Company”), and the Company hereby agrees to issue and sell to the Underwriters or Substituted Purchasers, an aggregate of $15,000,000 aggregate principal amount of 12.00% convertible unsecured subordinated debentures due December 31, 2024 (the “Offered Debentures”) of the Company at a price of $1,000 per Offered Debenture (the “Offering Price”). For greater certainty, the obligation of the Underwriters to purchase the Offered Debentures shall be reduced